Biederstädt, Alexander
Rezvani, Katayoun
Funding for this research was provided by:
german research foundation
lyda hill foundation
cancer prevention and research institute of texas (RP160693)
stand up to cancer (SU2C-AACR-DT-29-19)
national institutes of health (1 R01 CA211044-01, 5 P01CA148600-03, P50CA100632-16, P50CA127001, CA016672)
Article History
Received: 29 July 2021
Revised: 13 August 2021
Accepted: 18 August 2021
First Online: 28 August 2021
Declarations
:
: K.R., and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical for the licensing of the technology related to CAR-NK cell research. MD Anderson has implemented an Institutional Conflict of Interest Management and Monitoring Plan to manage and monitor the conflict of interest with respect to MDACC’s conduct of any other ongoing or future research related to this relationship. K.R., and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Affimed GmbH. Because MD Anderson is committed to the protection of human subjects and the effective management of its financial conflicts of interest in relation to its research activities, MD Anderson is implementing an Institutional Conflict of Interest Management and Monitoring Plan to manage and monitor the conflict of interest with respect to MD Anderson’s conduct of any other ongoing or future research related to this relationship. K.R. participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin, GSK, Caribou and Bayer.
Free to read: This content has been made available to all.